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Abstract
Many patients with persistent asthma can be controlled with inhaled corticosteroids (ICS).
However, a considerable proportion of patients remain symptomatic, despite the use of ICS. We
present systematically evidence that supports the different treatment options. A literature search
was made of Medline/PubMed to identify randomised and blinded trials. To demonstrate the benefit
that can be obtained by increasing the dose of ICS, dose-response studies with at least three
different ICS doses were identified. To demonstrate whether more benefit can be obtained by
adding long-acting β2-agonist (LABA), leukotriene antagonist (LTRA) or theophylline than by
increasing the dose of ICS, studies comparing these options were identified. Thirdly, studies
comparing the different "add-on" options were identified. The addition of a LABA is more effective
than increasing the dose of ICS in improving asthma control. By increasing the dose of ICS, clinical
improvement is likely to be of small magnitude. Addition of a LTRA or theophylline to the
treatment regimen appears to be equivalent to doubling the dose of ICS. Addition of a LABA seems
to be superior to an LTRA in improving lung function. However, addition of LABA and LTRA may
be equal with respect to asthma exacerbations. However, more and longer studies are needed to
better clarify the role of LTRAs and theophylline as add-on therapies.
Introduction
Inhaled corticosteroids (ICS) are the mainstay of current
asthma management and should be used in all patients
with persistent asthma. Many patients with persistent
asthma can be controlled with regular ICS. However, a
considerable proportion of patients treated with ICS
remain symptomatic, despite the use of low to moderate
doses (doses defined according to the ATS classification
for adults [1,2]: beclomethasone dipropionate (BDP) 200
– 1000 µg/d, budesonide 200 – 800 µg/d or fluticasone
propionate (FP) 100 – 500 µg/d) of ICS. Based on the dif-
ferences in potency and pharmacokinetics the doses could
also be defined differently [3,4]. Recent treatment guide-
lines [1,2,5,6] classify these patients as having moderate
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the recent guideline [2] the typical clinical features of step
3 asthma include symptoms daily, nocturnal symptoms at
least once a week, exacerbations that may affect activity or
sleep, forced expiratory volume in one second (FEV1) 60
– 80% of predicted or peak expiratory flow (PEF) between
60 and 80% of the personal best reading. Daily rescue
therapy is usually needed. Typical findings include low
values of PEF or FEV1, a marked variation in daily PEF
recordings and/or a significant response to bronchodila-
tors. Thus, asthma is not adequately controlled, and the
treatment needs to be optimized.
According to current guidelines the therapeutic options in
the treatment of asthma not adequately controlled by low
to moderate doses of ICS are as follows: 1. Increase in the
dose of the ICS, 2. Addition of long-acting β2-agonist
(LABA; formoterol or salmeterol), 3. Addition of a leuko-
triene receptor antagonist (LTRA; montelukast, pranlukast
or zafirlukast) and 4. Addition of theophylline. Currently,
the National Heart, Lung and Blood Institute guideline [2]
recommends addition of LABA as the first choice and
gives the other choices as secondary options, but leave the
clinician alone to make the decision without offering
comprehensive data to support the different options.
Recently, this "step-3" dilemma on the different treatment
options has gained attention [7,8]. Several of these
options have been separately assessed in several reviews,
systematic reviews and metaanalyses [7,9-16]. However,
no comprehensive reviews exist on the subject. The aim of
our article is to review the evidence that supports the
increase in the dose of ICS and use of the different "add-
on" options. Firstly to demonstrate the benefit that can be
obtained by increasing the dose of ICS, dose-response
studies with at least three different ICS doses were identi-
fied. Secondly, to demonstrate whether more benefit can
be obtained by adding LABA, LTRA or theophylline to the
treatment than by increasing the dose of ICS, we aimed to
identify studies where the addition of a LABA, LTRA or
theophylline to the treatment regimen was compared
with the addition of a corresponding plabeco to an
increased dose (usually doubled dose) of ICS. Thirdly, we
aimed to identify studies comparing the different "add-
on" options. In this review, we hope to help the clinician
facing the "step-3 dilemma" by presenting in a systematic
way the evidence obtained from randomised clinical trials
that supports the use of these different treatment options.
Methods
The paper reviews studies where participants were adults
or adolescents (≥12 years) with clinical evidence of
asthma not adequately controlled with ICS. The general
inclusion criteria in this review were: randomized,
blinded and controlled trials with either parallel group or
cross-over design published as a full-length paper. Ster-
oid-tapering studies were not included as they are difficult
to interpret. Studies published in abstract form only were
not included. Similarly, studies lasting less than 4 weeks,
containing less than 10 patients per group or studies con-
taining a significant proportion (>10%) of patients using
systemic steroids were excluded. Similarly "add-on" stud-
ies where a significant proportion (>10%) of patients
were not using inhaled steroids were excluded.
We made a search of Medline from January 1 1966 to
October 2001. All searches were limited to studies pub-
lished in the English language. To identify the latest stud-
ies published, another search was made by using the drug
names (budesonide, beclomethasone, fluticasone, flu-
nisolide, mometasone, triamcinolone, formoterol, salme-
terol, montelukast, pranlukast, zafirlukast, theophylline)
from Medline on October 2003. The searches were manu-
ally (HK) evaluated to identify studies fulfilling the inclu-
sion criteria and full papers were retrieved. In the case of
uncertainty based on the abstract full papers were
retrieved. All studies fulfilling the inclusion criteria for the
ICS dose-response studies or "add-on" studies (see below)
were scored for quality using the method described by
Jadad et al. [17]. Furthermore, relevant systematic reviews
were identified from the Cochrane Library (Issue 2, 2003).
In addition, some in vitro results or results from open,
non-randomized or uncontrolled trials or meta-analysis
of particular relevance to the present topic may be cited.
Inclusion criteria for dose-response studies with ICS
To find the dose-response studies with ICS the term "anti-
inflammatory agents, steroidal" was combined with the
term: "dose-response relationship, drug" (MeSH), which
combination produced 249 papers. To demonstrate the
dose-response effect of ICS only controlled studies with at
least three different ICS doses and a parallel-group design
were included. Studies using consecutive doses of steroids
were not included because it makes it impossible to differ-
entiate the dose-response relation from the time course
relation of efficacy.
Inclusion criteria for "add-on" studies with long-acting β2-
agonists, leukotriene antagonists and theophylline
When the basic search done with the term "anti-inflam-
matory agents, steroidal" was combined with another
made with terms: "salmeterol OR formoterol" it produced
97 papers, when combined with a search made with a
term "leukotriene antagonists" (MeSH), it produced 26
papers and when combined with a search with a term
"theophylline" (MeSH) it produced 342 papers. Only
studies where the addition of LABA, LTRA or theophylline
to the treatment with inhaled steroid was compared with
the addition of a corresponding placebo to an increased
dose (usually double-dose) of inhaled steroid werePage 2 of 25
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"add-on" options were identified.
Increasing the dose of inhaled corticosteroid
On the design of dose-response studies with ICS
We identified 14 studies [18-31] assessing the dose-
response relationship of ICS in the treatment of chronic
asthma. All included studies were of fair to excellent qual-
ity (Jadad score 3–5). The main characteristics of these
studies are presented in Table 1 (see Additional file 1).
The inclusion criteria in most of these studies were mod-
erate to severe chronic asthma but previous use of small to
moderate doses of ICS was not required in all studies. The
studies included patients with a relatively wide range of
FEV1 % predicted and based on that these patients belong
to steps 2–4 according to the recent guideline [2]. In all
except three studies a ≥12% reversibility in FEV1 or PEF in
response to a bronchodilator was required. There was 1
study that assessed the dose-response of budesonide, 7 of
FP, 1 of BDP, 3 of mometasone furoate, and 2 of triamci-
nolone acetonide. The studies utilized two main
approaches to identify a dose-response relationship.
Some studies considered dose-response relationship to be
present if the results obtained with the lowest and highest
dose of ICS were significantly different, whereas in others
the presence or absence of dose-response relationship was
characterized with more advanced statistical analysis (e.g.
analysis for linear trend or Jonckheere's nonparametric
trend test). In this review, both ways of analysis are
accepted as evidence for the presence of dose-response. In
the following discussion the important difference
between the formal dose-response studies presented in
this review and the results reported in some meta-analysis
is that the data of the meta-analyses may result from stud-
ies assessing one or more doses of ICS and comparing
their effects with placebo or baseline. Thus, the data
derived from some the published meta-analyses
[9,11,14,32], although showing a dose-response effect, is
obtained by combining different doses from several stud-
ies, and is not resulting from a strict dose-response rela-
tionship study. In addition, the data obtained using meta-
analysis may be derived only from one or two studies.
Overview on lung function and symptoms in the 14 
included studies
Studies with ICS show a statistically significant dose-
response effect for morning PEF and FEV1 in the treatment
of chronic asthma in 9 (69%) and 5 (31%) studies of the
14 studies included, respectively (Table 2a, see Additional
file 1). However, statistical analysis of dose-dependency
fails to show any significant dose-related effect for FVC in
5 (71%) studies of 7 where it was analysed. Similarly, no
statistical dose-dependency was found for evening PEF in
6 (50%) studies out of 12 where it was analysed (Table
2a, see Additional file 1). The total or daytime symptom
scores show a statistically significant dose-response effect
in 5 (38%) out of 13 studies, whereas nighttime symptom
score showed a dose-dependency in only three (25%)
studies out of 13 where it was analysed. A dose-response
for the rescue β2-agonist use was found in 4 (33%) out of
12 studies where it was analyzed (Table 2b, see Addi-
tional file 1). The difference between the highest and the
lowest dose of ICS was most often statistically significant
for morning PEF (7/12 studies; 58%) and to a lesser extent
for evening PEF (3/10 studies; 30%), FEV1 and total or
daytime symptom scores (both 2/12 studies; 16.7%),
night-time symptom score and rescue β2-agonist use
(both 1/11 studies; 9%) and FVC (0/6 studies; 0%). Sim-
ilarly, the difference between the two consecutive doses of
ICS was very seldom statistically significant (Table 2ab,
see Additional file 1). Thus, taken together, the results sug-
gest that morning and evening PEF and FEV1 are more sen-
sitive to show a statistically significant dose-response
effect for ICS, whereas symptom scores and rescue β2-ago-
nist use are in general less sensitive to the increase in ster-
oid dose. However, this conclusion may also be
influenced by the duration of treatment. Inclusion of rel-
atively short studies in this review, may either under- or
over-estimate the dose-response differences depending on
the outcome measure being used.
Beclomethasone dipropionate – studies included in this systematic 
review
The dose-response relationship of the effects of BDP (100
– 800 µg/d in two different formulations) was evaluated
in asthmatic subjects who had deterioration in asthma
control after discontinuation of ICS [18]. There was a sta-
tistically dose-dependent effect on morning PEF, FEV1,
FVC, days free from wheeze or chest tightness and β2-ago-
nist use, but not on evening PEF or nights free from
asthma related sleep disturbance (Table 2ab, see Addi-
tional file 1). The dose-response effects detected in this
study may reflect the fact that the patient population was
carefully identified to show a well-defined responsiveness
to ICS. Thereafter ICS were withdrawn to induce a clini-
cally meaningful deterioration of asthma control. Thus,
the design may not directly reflect clinical practice, where
a patient is symptomatic, despite the use of low to moder-
ate doses of ICS.
Beclomethasone dipropionate – other literature
A recent meta-analysis [10] analysed the dose-response
effect of BDP in the treatment of chronic asthma. Eleven
studies with variable methodological quality involved
1614 subjects were included in the analysis. Most of the
endpoints were based on only 1–2 studies. In asthmatic
patients not treated with oral steroids a small advantage of
BDP 800 µg/d over 400 µg/d was apparent for improve-
ment in FEV1 and morning PEF and reduction in night-
time symptom score compared to baseline. Studies thatPage 3 of 25
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demonstrated a significant advantage of the higher dose
compared to the lower dose for percentage improvement
in airway responsiveness to histamine and FEV1 compared
to baseline. No differences between higher and lower
daily doses of BDP were apparent for daytime symptoms,
withdrawals due to asthma exacerbations or oropharyn-
geal side effects.
Budesonide – studies included in this systematic review
A 6 weeks dose-response study in Japanese asthmatics pre-
viously not on ICS showed that increasing the dose of
budesonide (200–800 µg/d) [19] results in a dose-related
improvement in morning and evening PEF and daytime
and nighttime symptom scores, but not for FEV1. In this
study, there was no statistically significant difference
between the doubling doses of budesonide (Table 2ab,
see Additional file 1). Instead, even the lowest dose of
budesonide (200 µg/d) was superior to placebo in the
case of morning and evening PEF and daytime and night-
time symptom scores, but not for FEV1.
Budesonide – other literature
In a randomised, double-blind, placebo-controlled study
of parallel-group design lasting 12 weeks four different
doses of budesonide (200, 400, 800 and 1600 µg/d were
compared in patients suffering from moderate to severe
asthma. This study was not included in the systematic
analysis due to a high proportion of patients on oral glu-
cocorticoids (15.6%). Increasing the dose of budesonide
[33] results in a dose-related improvement in morning
PEF and FEV1, but not in evening PEF, FVC, symptom
scores or rescue β2-agonist use. Instead, even the lowest
dose of budesonide (200 µg/d) was superior to placebo
for all parameters studied. The improvement induced by
these low doses is much greater than the difference
between the lowest and highest doses of budesonide stud-
ied, despite the 8-fold difference in the dose (Figure 1)
[33]. There was a statistically significant difference only
between the lowest (200 µg/d) and the highest (1600 µg/
d) doses of budesonide when morning PEF or FEV1 were
analysed. Instead, the lowest (200 µg/d) or the highest
dose (1600 µg/d) did not differ from the two medium
doses (400–800 µg/d). When evening PEF, FVC, daytime
or nighttime asthma symptom scores or the use of rescue
medication were analysed, there was no significant differ-
ences between any of the studied budesonide doses [33].
The dose-relationship of budesonide in the treatment of
chronic asthma is a subject of a recent Cochrane review
[12]. In this meta-analysis including both children and
adults (n = 3907) in non-oral steroid-treated mild to
moderately severe asthmatics no clinically worthwhile
differences in FEV1, morning PEF, symptom scores or res-
cue β2-agonist use were apparent across a dose range of
200–1600 µg/d. However, in moderate to severe asthma
there was a significant reduction in the likelihood of trial
withdrawal due to asthma exacerbation with budesonide
800 µg/d compared with budesonide 200 µg/d. The
reviewers also conclude that budesonide exhibits a signif-
icant improvements favouring high dose (1600 µg/d)
over low dose (200 µg/d) for improvement in FEV1 in
severe asthma [12]. Another recent meta-analysis combin-
ing 3 placebo-controlled studies with at least two different
budesonide doses demonstrated a statistically significant
dose-response for morning PEF and FEV1 but not for
evening PEF [14].
Fluticasone propionate – studies included in this systematic review
The dose-dependency of FP has been studied in seven
studies in patients with mild to moderate asthma. In two
of the studies, patients were previously not on ICS (Table
1, see Additional file 1). The difference between the high-
est and lowest dose was 4- to 20-fold. In all studies almost
all parameters improved significantly better with all doses
of FP as compared with placebo. Only three studies
[20,21,26] show a dose-response effect on morning PEF,
only two studies [20,26] show a dose-response relation-
ship for evening PEF and rescue medication use and only
one study [20] shows a dose-response relationship for
FEV1, FVC and daytime symptom score (Table 2ab, see
Additional file 1). When different doses of FP (50–200–
1000 µg/d) were studied in a randomized, double-blind
dose-response setting, there was no difference in FEV1,
FVC, evening PEF, symptom scores, use of rescue medica-
tion or the number of night awakenings between the low-
est and highest FP dose, despite a 20-fold difference in the
dose [21]. Only for morning PEF was the high (1000 µg/
d) dose of FP better than the two lower doses, whereas
even the lowest dose of FP (50 µg/d) was significantly bet-
ter than placebo in improving all these parameters.
In a dose-response study [20] with patients with sympto-
matic chronic asthma (n = 672) patients were randomized
to four different doses of FP (100, 200, 400, 800 µg/d). FP
improved lung function and symptoms in a dose-related
manner. The linear trend for doubling the dose of FP was
calculated to be as follows: morning PEF increased 4.3 L/
min (95% CI 1.8–6.8) and FEV1 increased 0.03 L (95% CI
0–0.05 in two weeks). How does this translate into clini-
cal practice? When assessing a response to a bronchodila-
tor or when assessing a response to inhaled or oral steroid
an improvement of 10–20% above the previous values is
often considered significant. Thus, in the above study, this
would mean >36 L/min increase in morning PEF values.
Recently, the average minimal patient perceivable
improvements have been estimated as 18.8 L/min for PEF
and 0.23 L for FEV1 [34]. Based on that the increase in
lung function obtained by doubling the dose ofPage 4 of 25
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limited clinical benefit.
Fluticasone propionate – other literature
In a recent meta-analysis [9] the dose-response relation of
inhaled FP in adolescents or adults with asthma in eight
studies [n = 2324] employing 2–3 different doses of
inhaled FP were analysed. The dose-response curve for the
raw data began to reach a plateau at around 100–200 µg/
d and peaked by 500 µg/d. A negative exponential model
for the data indicated that 80% of the benefit at 1000 µg/
d was achieved at doses of 70–170 µg/d and 90% by 100–
250 µg/d. A quadratic meta-regression showed that the
maximum achievable efficacy was obtained by doses of
around 500 µg/d. Another recent meta-analysis [11] of 28
studies with 5788 patients (children and adults) with
chronic asthma evaluated the dose-response effect of FP,
compared to placebo. Evidence for a dose-response effect
was apparent for likelihood of trial withdrawal due to lack
of efficacy, change in FEV1, morning PEF, evening PEF,
nighttime awakening score and physician-rated efficacy. It
is important to appreciate that this was only evident when
improvements over placebo were compared for the high-
est dose of FP (1000 µg/d) and lowest dose of FP (100 µg/
d). There were no significant differences when any other
doses were compared (e.g. FP 200 v 100 µg/d, FP 500 v
200 µg/d, FP 1000 v 500 µg/d). Sixty percent (0.31 L; 95%
CI 0.27–0.36 L) of the effect on FEV1 with FP 1000 µg/d
(0.53 L; 95% CI 0.43–0.63 L) was achieved with tenth of
the dose. No dose-response effect was apparent for change
in symptom score or for rescue β2-agonist use [11].
Another recent meta-analysis from the same authors [32]
found a statistically significant advantage of FP 200 µg/d
over 100 µg/d for morning PEF (6 L/min; 95% CI 1–10 L/
min), evening PEF (6 L/min, 95% CI 2–11 L/min) and
night-time awakening score (0.17, 95% CI 0.04 – 0.30),
but not for FEV1, daily symptom score, night-time awak-
enings and daily use of rescue β2-agonist use. No signifi-
cant advantage was obtained with the use of FP at doses of
400–500 µg/d over 200 µg/d for morning or evening PEF,
FEV1, daily symptom score or rescue β2-agonist use.
Patients treated with higher dose (800 – 1000 µg/d) of FP
Mean change from baseline in morning peak expiratory flow (PEF) in patients treated with placebo or various doses of budesonideFigure 1
Mean change from baseline in morning peak expiratory flow (PEF) in patients treated with placebo or various doses of budeso-
nide. A significant dose-response effect is seen. However, it should be noted that the difference between placebo and low-dose 
budesonide is greater than the difference between low-dose budesonide and high-dose budesonide and that there is no statis-
tically significant difference between the various doses of budesonide. Reproduced from reference 33 with permission.Page 5 of 25
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PEF (22 L/min, 95% CI 15–29 L/min) and evening PEF
(13 L/min, 95% CI 6–19 L/min) compared to the lower
dose (50–100 µg/d). Another recent meta-analysis [14]
including eight trials with at least 2 different doses of FP
demonstrated a statistically significant dose-response in
morning PEF, evening PEF and asthma symptom score
but not in FEV1 or β2-agonist use.
Mometasone furoate and triamcinolone acetonide – studies included 
in this systematic review
Mometasone furoate is a corticosteroid closely related to
FP and is being investigated in a dry powder inhalation
formulation for the treatment of asthma [35]. Studies
with mometasone furoate [27-29] show a dose-related
efficacy in the treatment of mild to moderate asthma
when morning PEF is analysed (Table 2a, see Additional
file 1). Interestingly, even doubling doses of mometasone
furoate produced statistically significant improvements in
morning and evening PEF (Table 2a, see Additional file 1)
[27-29]. Occasionally, a statistically significant dose-
dependency or difference between the highest and lowest
dose was found for evening PEF, FEV1 or daytime or total
symptom score. In contrast, no significant dose-depend-
ency was found for FVC, nighttime symptom score or res-
cue β2-agonist use (Table 2ab, see Additional file 1).
Linear trend analyses showed a dose-response for triamci-
nolone acetonide (TAA) in the treatment of moderate to
severe asthma across the dose-range of 150 to 600 µg/d or
200 to 1600 µg/d for most variables in the two studies
included in this review (Table 2ab, see Additional file 1)
[30,31]. Occasionally, a statistically significant difference
was reported even between two consecutive doses of TAA.
As compared with placebo, therapeutic activity was gener-
ally evident at doses of 150–200 µg daily for all variables
with significant clinical efficacy demonstrated for all
doses.
Mometasone furoate and triamcinolone acetonide – other literature
A four-week randomised, double-blind, double-dummy
and parallel group study [36] comparing the efficacy and
safety of mometasone furoate administered by metered
dose inhaler (112, 400 and 1000 µg/d) with BDP (336 µg/
d) and placebo recruited adult patients with moderate
asthma (n = 395). The patients were required to have a sta-
ble ICS dose, FEV1 or 50–90% and a bronchodilator
response of ≥15% in absolute FEV1 at baseline. This study
reported significantly better improvement in FEV1, FVC
and morning PEF with doses of 400 and 1000 µg/d than
with 112 µg/d. Also, physician's evaluation of asthma
symptoms, but not salbutamol use was significantly better
with dose 1000 µg/d than with 112 µg/d. This study,
although fulfilling the criteria for dose-response study as
defined in materials and methods, was excluded from the
systematic evaluation, as the published statistical analysis
did not include any formal dose-response analysis, and
the reported difference between different mometasone
doses always required a statistically significant difference
to the active comparator BDP.
In contrast to the results presented in this review (Table
2ab, see Additional file 1), a meta-analysis [14] including
2 studies with mometasone furoate (200 µg/d versus 400
µg/d) failed to show any significant dose-response in
FEV1. In the meta-analysis, there was not enough data to
analyse other parameters than FEV1. The 3 studies [27-29]
included in this review were not included in the meta-
analysis [14]. The data suggests that 200 µg/d of mometa-
sone furoate may be a relatively small dose. As both the
inhaler device and mometasone have not been available
for the treatment of asthma, it is difficult to define their
exact position in the treatment of asthma, although there
are data to suggest that a total daily dose of 400 µg of
mometasone furoate administered with dry powder
inhaler may be equal to total daily dose of 500 µg of FP
via a Diskhaler or a daily dose of 800 µg budesonide via a
Turbuhaler [28,29].
A placebo-controlled, double-blind parallel-group study
assessed the effects of three different doses of TAA (450,
900 and 1800 µg/d for 12 weeks; delivered using a non-
chlorofluorocarbon propellant) in patients with chronic
symptomatic asthma and using ICS [37]. The data for all
variables (FEV1, FEF25–75, morning and evening PEF,
symptom scores and rescue salbutamol use) shows that
even the lowest dose significantly differs from placebo,
and there appears to be no clear dose-response. However,
no formal statistical analysis was reported for the presence
of a dose-response and thus this study is not included in
Tables 1–2. A recent meta-analysis [14] including 3 stud-
ies with TAA, demonstrated a statistically significant dose-
response in morning PEF, evening PEF and asthma symp-
tom score, but not in FEV1.
Conclusions on the effects of ICS on lung function and 
asthma symptoms
Taken together these results indicate that the change in the
ICS dose from low dose to moderate dose is at the flat part
of the ICS dose-response curve for most lung function and
symptom parameters studied (Figure 2). Furthermore, it
appears that the low and moderate doses of currently used
ICS are in the flat part of the steroid dose-response curve.
Thus, it is predicted that doubling the dose of ICS is not
sufficient to significantly improve lung function or reduce
symptoms. Rather, the data suggest that the increase in the
dose of ICS should be at least 4-fold to produce a clinically
significant improvement in variables such as symptoms,
use of rescue β2-agonists, PEF or lung function. However,
the steepness of the dose-response curve for differentPage 6 of 25
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evaluation of different sequential doses of budesonide in
patients with mild-to-moderate asthma (38) shows that
the dose-response curves for FEV1/PEF and FEF25–75 are
not identical. Similarly, the dose-response curves of
budesonide on adenosine monophosphate (AMP) and
methacholine bronchial challenges were significantly dif-
ferent [38]. It should also be noted that patients often
receive higher doses of ICS in their daily routine treatment
than required [3].
The studies discussed above present mean data for groups
of patients, but do not address the issue of differences in
responsiveness to the anti-inflammatory effects of corti-
costeroids between individual patients. It may be possible
that increasing the dose of ICS may be beneficial for some
patients.
Is there a dose-response in the anti-inflammatory effects 
of ICS?
Studies included in this systematic review
We were not able to identify any studies that would have
studied the dose-dependency of the anti-inflammatory
effects of ICS in asthma and would have satisfied the
inclusion criteria for the present review.
Other literature
In a study [39] with patients with chronic asthma (n = 66)
treated with moderate doses of ICS the dose-dependency
of consecutive doses of budesonide (800, 1600 and 3200
µg/d) and FP (500, 1000 and 2000 µg/d) were studied.
Budesonide increased methacholine PD20 from 259 to
467 µg and FP from 271 to 645 µg, both showing a dose-
dependency. However, no statistical comparison was
made between individual doses. The PD20 was increased
1.67-fold and 1.96-fold when the patients were switched
from the lowest dose to the highest dose of budesonide
and FP, respectively. An apparently dose-dependent
decrease in the blood eosinophil count was obtained with
budesonide but not with FP treatment [39]. In contrast,
no significant differences were observed for either treat-
ment, when morning or evening PEF, symptom scores,
and consumption of β2-agonist were analysed. Allergen
PC15 and methacholine PC20 values were determined
before and after treatment with budesonide at 200, 400
and 800 µg/d for 7 days in a double-blind, randomized
and cross-over study (6 day washout period) in eleven
atopic subjects with inhalation allergy [40]. The allergen
PC15 and methacholine PC20 were significantly larger for
all doses of budesonide as compared with placebo, but
there was no significant difference between the 3 doses of
budesonide. In an open trial with patients with moderate
to severe asthma the effects of progressively increasing
doses of budesonide (400, 800, 1600 and 2400 µg/d)
were studied [41]. Budesonide decreased the blood eosi-
nophil count in a dose-dependent manner. In a double-
blind, randomized placebo-controlled study combining
two separate studies, the dose-dependency of the anti-
inflammatory effects of budesonide (100, 400 and 1600
µg/d) was assessed in patients with mild asthma (n = 31).
Based on trend analysis, there were dose-dependent
changes in exhaled NO, sputum eosinophils and PC20 to
inhaled budesonide but a plateau response of exhaled NO
was found at a dose of 400 µg/d [42]. In a study with a
novel ICS ciclesonide, its effects were studied in a parallel-
group, double-blind, placebo-controlled, randomized
cross-over study (washout period 3–8 weeks) in patients
(n = 29) with mild to moderate asthma [43]. Compared
with placebo, ciclesonide for 14 days (100, 400 and 1600
µg/d) reduced airway responsiveness to AMP by 1.6, 2.0
and 3.4 doubling doses, respectively, and this effect was
dose-dependent. A significant reduction in the percentage
of eosinophils in induced sputum was observed after 400
and 1600 µg daily ciclesonide, but this was not dose-
dependent. Sputum eosinophil cationic protein (ECP)
was significantly reduced after 400 µg daily ciclesonide
only, and no dose-dependent effect was seen. In a recent
single-cohort, prospective placebo-controlled study with
four 1 week periods with nonsteroid-treated asthmatic
patients (n = 15) the effects of different doses of BDP
(100, 400 and 800 µg/d) were measured on FEV1, exhaled
nitric oxide (FENO) and methacholine PC20 [44]. All
doses of BDP resulted in a significant change in FEV1 and
methacholine PC20 from baseline or placebo treatment,
The dose-response curve of inhaled glucocorticoidsFigure 2
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doses of BDP resulted in a significant change in FENO
from placebo treatment, but with significant separation of
only the 100 µg and 800 µg doses by FENO. Another
study assessed the dose-response relationship of the anti-
inflammatory effects of BDP (50, 100, 200 and 500 µg/d)
in the treatment of mild to moderate asthma for 8 weeks
in a randomised, placebo-controlled, double-blind trial of
parallel-group design [45]. Maintenance ICS therapy was
discontinued and patients were randomised to different
treatment groups and inflammatory markers such as
exhaled NO, sputum eosinophil counts and PD15 to saline
were followed. There was a significant linear relationship
between BDP dose and exhaled NO concentration, FEV1
and changes in sputum eosinophils at the end of treat-
ment. In contrast no relationship was found between BDP
dose and PD15 to saline. However, the results of this study
may be confounded because the patients were treated
with oral prednisolone for two days in the beginning of
the study.
In a recent randomized and double-blinded study, 12
atopic mild stable asthmatic subjects were treated with
placebo or mometasone furoate (100, 200 and 800 µg/d)
for six days [46] in a cross-over fashion. All three doses of
MF demonstrated similar attenuation of early responses
and allergen-induced airway hyperresponsiveness relative
to placebo with no dose-response relationship. In con-
trast, the late maximal % fall in FEV1 after placebo treat-
ment was 24% and was significantly reduced in a dose-
dependent manner to 12%, 11% and 6% for the 100, 200
and 800 µg daily treatments. The allergen-induced spu-
tum eosinophilia (×104 cells/ml) 24 h after challenge dur-
ing placebo treatment was 60.2 and was significantly
reduced to 24.0, 15.3 and 6.2 for the 100, 200 and 800 µg
daily treatments, respectively. Although a statistically sig-
nificant dose-response relationship was present, the dif-
ference between the lowest and highest dose (8-fold
difference) for late maximal fall in FEV1 or allergen-
induced sputum eosinophilia was less than the difference
between placebo and the lowest dose of MF.
Taken together, the results suggest that there is tendency
towards slightly higher anti-inflammatory efficacy with
higher doses of ICS. At the moment there are only a few
studies that assess the dose-dependency of the anti-
inflammatory effects of ICS. Most of these studies
included only small numbers of patients. However,
despite the 4–8–16-fold differences in the doses of ICS
studied, it has not been easy to demonstrate the dose-
dependency of the anti-inflammatory effects of inhaled
glucocorticoids. Thus, based on the scarce published evi-
dence we would predict that doubling of the commonly
used low to moderate doses of ICS is likely to produce
only a small increase in the anti-inflammatory effect, sug-
gesting that inflammation may be suppressed in most
patients by relatively low doses of ICS.
Is there a dose-response with the adverse effects of ICS?
Glucocorticoids suppress corticotrophin levels, which
may eventually lead to atrophy of the adrenal cortex and
diminished levels of endogenous cortisol. The diminished
levels of endogenous cortisol or reduced cortisol excretion
have been used as markers of systemic activity of ICS.
These systemic effects may include osteoporosis, behav-
ioural effects, growth suppression, posterior subcapsular
cataracts, risk for ocular hypertension and glaucoma as
well as skin thinning and bruising [47]. In the following
sections the literature on the dose-related effects of differ-
ent steroids on HPA axis as well as on local adverse effects
is discussed.
Studies included in the systematic review
Of the 14 studies included in this review, in 8 the effects
on HPA-axis suppression were analysed. No data on the
effects of BDP, budesonide or TAA on HPA-axis were
reported. Six of the 7 randomised, double-blind dose-
response studies with FP also analysed its effect on HPA
axis, measuring either basal morning cortisol levels, post-
cosyntropin stimulation test levels or urinary excretion of
cortisol metabolites (Table 2b, see Additional file 1).
Only one study reported a statistically significant dose-
response effect (3% decrease per doubling dose of FP) in
morning plasma cortisol levels [20] and one study [21]
reported slight transient reductions in urinary free cortisol
and urinary 17-hydroxy steroids in the group receiving the
highest dose of FP (1000 µg/d). However, in 5 studies
made with FP, no dose-related effects on HPA-axis sup-
pression were described (Table 2b, see Additional file 1).
There was no indication for the dose-dependent HPA-axis
suppression in 2 studies with mometasone furoate. One
needs to note that these studies were not planned and
powered to detect differences in systemic or adverse
effects.
Beclomethasone dipropionate – other literature
The dose-related effects of HFA-BDP (200–800 µg/d) were
studied in 43 steroid-naïve asthmatic patients in a rand-
omized double-blind fashion for 14 days [48]. When the
HFA-BDP dose increased a greater decrease in the percent
change from baseline in steady state 24 h urinary free cor-
tisol was found suggesting a dose-response. Despite the
observed statistically significant differences between pla-
cebo and the two highest dose-groups in mean percent
change in 24 h urinary free cortisol, only one patient
among all the treatment groups fell below the reference
range for this parameter. In another small, randomized
study 26 steroid-naïve asthmatic patients were treated
with increasing doses of BDP (400 – 1600 µg/d) [49].
Only the highest dose of BDP produced a significantPage 8 of 25
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Cochrane review [10], the dose-response relationship of
BDP on HPA axis function was analysed. Only two small
studies with adult patients not treated with oral steroids
were identified, and showed no effect on morning plasma
cortisol by two to five-fold increase in the BDP dose.
Budesonide – other studies
A randomized double-blind study with consecutive dose
design [39] comparing FP (500–2000 µg/d) and budeso-
nide (800–3200 µg/d) reported that budesonide, but not
FP (or at least to a lesser extent) reduced 24 h urine corti-
sol excretion, plasma-cortisol and serum osteocalcin in a
dose-related manner. Similar results have been reported
from an open, randomized, parallel group trial with
budesonide at doses of 400, 800, 1600 and 2400 µg/d for
2 weeks at each dose level, in adult patients with moderate
to severe asthma [41]. Budesonide decreased the 24 h uri-
nary cortisol excretion, serum cortisol and osteocalcin in
a dose-dependent manner. In a randomized, double-
blind parallel-group study [33], budesonide (1600 µg/d
for 12 weeks) induced a mean change from baseline in
synthetic corticotrophin (cosyntrophin)-stimulated
plasma cortisol levels that was significantly different from
placebo and the lowest dose of budesonide. However, the
difference from placebo was only 10%, and all other doses
of budesonide were not statistically different from pla-
cebo. In contrast, the mean basal morning plasma cortisol
levels among different budesonide treatment groups and
placebo did not differ. In a randomized cross-over study
[50], budesonide (1600 µg/d) reduced serum osteocalcin
and blood eosinophil count as compared with placebo,
but these effects were not dose-dependent. In contrast,
budesonide (400–1600 µg/d) had no significant effects
on adrenal function as assessed by 8 am serum cortisol or
overnight urinary cortisol excretion. In a recent open
study, budesonide (400–1600 µg/d) was given to patients
with mild to moderate asthma (n = 26) sequentially for 3
weeks each dose, a total of 9 weeks [38]. There was a sig-
nificant dose-related suppression of morning cortisol lev-
els and overnight urinary cortisol values, but not of serum
osteocalcin. For example, the percentages of patients with
a stimulated plasma cortisol response less than 500 nM
were 7% at baseline, 13% at 400 µg/d, 40% at 800 µg/d
and 66% at 1600 µg/d. The authors reported that the pro-
portions of patients with a beneficial airway response
together with a minimal systemic response – that is, an
optimal therapeutic index – were approximately 50% at
all three doses of budesonide. However, the proportion of
patients with a good airway response together with a
marked systemic response – that is, a suboptimal thera-
peutic index – increased from 4% at low dose to 38% at
high dose [38]. In a recent Cochrane meta-analysis, statis-
tically significant, dose-dependent suppression by budes-
onide of 24 hour urinary free cortisol excretion and serum
cortisol post synthetic ACTH infusion over the dose range
800 – 3200 µg/d were apparent, but the authors con-
cluded that the clinical significance of these findings is
unclear [12].
Fluticasone propionate – other literature
FP has also been shown to suppress 8 am serum cortisol
and urinary cortisol/creatinine ratio in a dose-dependent
manner in a single-blind placebo-controlled cross-over
study for 9 days in patients (n = 12) with mild to moder-
ate asthma [51]. Similar dose-dependent suppression of
adrenocortical activity was reported in four other studies
with patients with mild to moderate asthma from the
same research group [52-55]. Interestingly, the suppres-
sive effects of FP on adrenocortical activity were greater
than those observed on osteocalcin or eosinophils.
A Cochrane review [11] collected data on the effects of FP
on HPA-axis function. Significant differences were not
apparent between any daily dose of FP in the range of
100–1000 µg/d and placebo on basal plasma cortisol val-
ues or urinary cortisol excretion. However, the authors
were not able to make a meta-analysis of the cortisol val-
ues. In another Cochrane review [32] the same authors
found no evidence for dose-dependent suppression of
HPA function. However, no decent meta-analysis could
be made due to limited availability of data. In contrast to
these findings another meta-analysis [47] found that FP
exhibits a significantly steeper dose-related systemic bioa-
vailability than BDP, budesonide, or triamcinolone when
21 studies of urinary cortisol levels and 13 studies of sup-
pression of 8 am plasma cortisol levels were analysed.
Thus, there clearly exists a discrepancy in the published lit-
erature concerning the systemic effects of FP.
Based on the recent Cochrane review and meta-analysis
[32] it seems obvious that there is a dose-response rela-
tionship in the appearance of local side-effect hoarseness
and/or dysphonia so that FP at doses of 400–500 µg/d
and 800–1000 µg/d has a significantly higher risk than at
lower doses (50–100 µg/d). Similarly FP at doses of 50–
100 µg/d induces significantly less oral candidiasis than at
doses of 800–1000 µg/d. However, there seemed to be no
significant difference in the incidence of sore throat/phar-
yngitis between any of the FP doses. Another systematic
review [16] collected data from fluticasone studies and
calculated NNT (number needed to treat) to prevent wors-
ening of asthma and NNH (number needed to harm) to
induce oral candidiasis. Three patients needed to be
treated with fluticasone 100 µg/d to prevent worsening of
asthma (NNT 3), and for fluticasone 1000 µg/d the NNT
was 2.1 patients. In contrast, the dose-response curve for
side effects was steep. For a dose of fluticasone 100 µg/d,
oral candidiasis developed in one of every 90 subjectsPage 9 of 25
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µg and 2000 µg daily were 23 and 6, respectively.
Triamcinolone acetonide – other literature
In two randomized studies, TAA in the dose range of 400–
1600 µg/d [50,51] did not significantly affect 8 am serum
cortisol or the 24 h or overnight urinary excretion of cor-
ticosteroid metabolites. In an open non-controlled 6
months study with 400–800–1600 µg/d TAA the plasma
cortisol levels before and after cosyntrophin injection
were analysed in patients with asthma [56]. Although all
treatment regimens caused some reduction in the 24 h
excretion of corticosteroid products, none of the mean
values was below the normal ranges and no significant
suppression in the cosyntrophin test was seen. The mean
data indicated that TAA had overall no significant effect
on adrenal function at any dose or at any time. However,
three patients exhibited some reduction in adrenal func-
tion. In another small, randomized study 26 steroid-naïve
asthmatic patients were treated with increasing doses of
TAA (800 – 3200 µg/d) [49]. Only the highest dose of TAA
produced a significant suppression of 24 h urinary free
cortisol.
Conclusions on the effects of ICS on HPA axis and local 
side effects
Taken together, the data on the systemic adverse effects of
ICS is conflicting and seems also to reflect the study
design. Several studies have measured only the basal
morning cortisol levels or levels after stimulation with
high cosyntrophin doses. However, these may be insensi-
tive markers for HPA-axis suppression [47]. Different, a
possibly more sensitive endpoint could be plasma cortisol
profile during 20–24 h period, which has been shown to
be affected by a short course of fluticasone and/or budes-
onide or even after single inhaled doses [57-59]. There is
disagreement between the relative potency of budesonide
and FP on HPA-axis function. In addition to the different
ways to measure HPA-axis function, this may be due to
the use of different inhalers, duration of the treatment
period, the selection of the patient group or different
design and sponsoring of the studies by pharmaceutical
companies. In addition there are differences in the deliv-
ery of ICS between normal subjects and patients with
asthma and in patients with severe versus mild asthma
[60-62]. Although generally safe, it appears that there is at
least some degree of dose-dependency in the HPA-axis
effects of inhaled steroids. Some smaller studies
[39,41,54] suggest that there is a significant decrease in
the therapeutic index with higher doses of ICS. Recently, a
statistical meta-analysis using regression was performed
for parameters of adrenal suppression in 27 studies [47].
Marked adrenal suppression, and thus a marked risk for
systemic adverse effects, occurs at doses of ICS above 1500
µg/d (budesonide and BDP) or 750 µg/d (FP), although
there is a considerable degree of inter-individual suscepti-
bility. Meta-analysis showed significantly greater potency
for dose-related adrenal suppression with FP compared
with BDP, budesonide, or TAA. The author concludes that
ICS in doses above 1500 µg/d (750 µg/d for FP) may be
associated with a significant reduction in bone density
[47]. Long-term, high-dose ICS exposure increases the risk
for posterior subcapsular cataracts, and to a much lesser
degree, the risk for ocular hypertension and glaucoma.
Skin bruising, which correlates with the degree of adrenal
suppression, is most likely to occur with high-dose expo-
sure [47].
Adding a long acting-β2-agonist (LABA)
The rationale
LABA provide long-lasting relaxation of airway smooth
muscle, while the ICS provide potent topical anti-inflam-
matory action. In addition to these complementary
actions, β2-agonists may have several other actions that
may contribute to their efficacy in relieving asthma symp-
toms. β2-Agonists inhibit plasma exudation in the airways
by acting on β2-receptors on postcapillary venule cells.
They inhibit the secretion of bronchoconstrictor media-
tors from airway mast cells and may inhibit release of
mediators from eosinophils, macrophages, T-lym-
phocytes and neutrophils. In addition, β2-agonists may
have an inhibitory effect on the release of neuropeptides
from sensory nerves [63]. Corticosteroids may also
increase the expression of β2-receptors in inflammatory
cells to overcome the desensitisation in response to
chronic β2-agonist exposure [64]. In addition, LABA may
prime the glucocorticoid receptor facilitating activation by
corticosteroids [65,66].
Design of 12 LABA add-on studies included in the review
The literature search identified 3 studies with formoterol
[67-69] and 9 studies with salmeterol [70-78]. All these
studies included adult or adolescent patients with symp-
tomatic asthma. Generally, patients used low to moderate
doses of inhaled glucocorticoids. In two studies [68,73]
previous use of ICS was not required. In all studies PEF or
FEV1 reversibility of at least 10–15% was required (Table
3, see Additional file 1). Diurnal or period PEF variation
>15% was required in four studies. FEV1 of >(40)–50% of
predicted and a clearly positive symptom score was
required in most studies (Table 3, see Additional file 1).
In general, the mean FEV1 (% predicted) varied between
61 and 87% in different studies, being 61–70% in 4 stud-
ies, 70–80% in 3 studies, 81–87% in two studies and was
not reported in three studies. The mean absolute PEF val-
ues varied from 299 to 404 L/min and FEV1 from 2.12 to
2.54 L (Table 5, see Additional file 1). Thus, the patient
population in these studies represents mainly those with
moderate to severe persistent asthma. This as well as the
fact that patients with recent exacerbations are excludedPage 10 of 25
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In one study [78] patients were required to have at least
two exacerbations during the previous year to be eligible
for the inclusion in the study. One study [68] was per-
formed in patients mainly affected with mild persistent
asthma. In salmeterol and formoterol studies, the com-
parison dose of ICS was increased 2–2.5 (-4)-fold,
whereas in the formoterol study [67] the comparison dose
of budesonide was 4-fold higher (Table 4, see Additional
file 1). Another significant difference between formoterol
and salmeterol studies is that in the formoterol [67] study
the main outcome parameter was the incidence of exacer-
bations whereas the salmeterol studies mainly focused on
lung function and asthma symptoms. Most studies
allowed a constant dose of theophylline but not oral ster-
oid use (Table 3, see Additional file 1). Six out of the 12
studies excluded patients having previous exacerbations
(generally during previous month). Only 2 studies lasted
one year [67,68], whereas most studies lasted at least 24
weeks. Most reports did not identify whether the study
were performed by respiratory specialists or general prac-
titioners. All studies were financially supported by phar-
maceutical companies.
Lung function and asthma symptoms
Formoterol – studies included in this systematic review
The addition of formoterol was compared with the
increase (4-fold) in the dose of inhaled budesonide (from
200 µg/d to 800 µg/d) in patients with moderate to severe
symptomatic chronic asthma [67]. The patients (n = 852)
in this study had a FEV1 of at least 50% of predicted (mean
75–76%) with an increase in FEV1 ≥15% after inhalation
of terbutaline. Addition of formoterol was superior to the
increase in steroid dose in increasing FEV1 and morning
PEF (Figure 3A; Table 5, see Additional file 1). Similarly,
addition of formoterol was equal or superior to the 4-fold
increase in ICS dose in reducing day- or night-time symp-
tom scores or rescue medication use (Table 6, see Addi-
tional file 1). Most importantly, the effect of formoterol
was sustained over the one-year treatment period. In this
study, no statistical comparison was made between the
low-dose budesonide + formoterol and high dose budes-
onide groups.
Another study [69] compared the addition of formoterol
(4.5 µg bid) to a small dose of budesonide (160 µg/d) in
single inhaler (Symbicort®) with an increased dose of
budesonide (400 µg/d) in adults with mild to moderate
asthma (mean FEV1 81–82%) not fully controlled on low
doses of ICS alone. The increase in mean morning and
evening PEF was significantly higher for budesonide/for-
moterol compared with budesonide alone. In addition,
the percentage of symptom-free days and asthma control
days were significantly improved in the budesonide/for-
moterol group. Budesonide and formoterol decreased the
relative risk of an asthma exacerbation by 26% as com-
pared with higher dose budesonide alone.
Formoterol add-on study showing forced expiratory volume in one second (FEV1) (panel A, from ref 64 with permission) and the estimated yearly rates (no. patients/year) of severe asthma exacerbations in the diff rent treatment groups of the study (pan l B)igure 3
Formoterol add-on study showing forced expiratory volume in one second (FEV1) (panel A, from ref 64 with permission) and 
the estimated yearly rates (no. patients/year) of severe asthma exacerbations in the different treatment groups of the study 
(panel B). For estimated yearly rate of exacerbations, the P-values given were formoterol vs placebo P = 0.01 and lower vs 
higher dose of budesonide P < 0.001.Page 11 of 25
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addition of formoterol were confirmed in patients with
mild asthma (mean FEV1 86–87% of predicted and using
approximately 1 rescue inhalation per day) [68]. In this
study, the addition of formoterol was superior to dou-
bling the dose of budesonide in increasing FEV1 and
morning PEF in the patients already treated with a low
dose of ICS, but not in steroid-naïve patients (Table 5), or
in reducing the percentage of days with symptoms,
number of rescue inhalations or nights with awakenings
in the patients with mild persistent asthma already treated
with low doses of ICS (Table 6, see Additional file 1).
A subgroup of the patients participating in the formoterol
study [67] was analysed for asthma quality of life param-
eters using the Asthma Quality of Life Questionnaire
(AQLQ) [79]. Following randomisation there was a signif-
icant increase in the AQLQ score only in the group with
higher budesonide + formoterol group. Although the pat-
terns of mean responses for AQLQ scores and for the clin-
ical variables were very similar, correlations between
change in AQLQ scores and change in clinical measures
over the randomized period were only weak to moderate
(maximum r = 0.51). The data confirm that the benefit
from the addition of formoterol is sustained. However,
instead of improving pulmonary function parameters
patients are usually more interested in how their normal
everyday life and activities are limited by the disease. The
analysis of AQLQ parameters and their comparison with
the clinical data in that analysis also suggest that if only
pulmonary function parameters are to be analysed, the
benefits of addition of LABA to the treatment may be over-
estimated. Also, it should be noted that no correlation has
been found between measures of pulmonary function and
daytime asthma symptoms [80].
Formoterol – other literature
As compared with the abovementioned three studies, sim-
ilar superiority of addition of formoterol on morning PEF,
rescue medication use and asthma symptoms were
reported in an open randomised parallel-group study
comparing the addition of formoterol to the low-dose
BDP with 2-fold higher dose of BDP in patients suffering
from symptomatic asthma, despite the use of inhaled BDP
[81].
Salmeterol – studies included in this systematic review
Addition of salmeterol as compared with the increase in
the dose of ICS BDP or FP has been studied in 9 ran-
domised parallel group studies with 3651 patients with
moderate to severe persistent asthma (Tables 3 and 4, see
Additional file 1). Addition of salmeterol improved FEV1
better than increasing the dose of ICS 2–4-fold in 5 studies
(analysed in 6 studies) and mean morning PEF in 7 stud-
ies (analysed in 9 studies), respectively (Table 5, see Addi-
tional file 1). Similarly, addition of salmeterol was
significantly better than the increase in the dose of ICS in
increasing the number of days or nights without symp-
toms or without rescue medication or reducing day- or
night-time symptom score as well as daytime or night-
time rescue medication use in most studies (Table 6, see
Additional file 1). However, although addition of salme-
terol seems to be superior to increased dose of ICS, a sta-
tistically significant difference was not always reached
(Tables 5 and 6, see Additional file 1) in the single studies
when FEV1, morning PEF, asthma symptom scores or res-
cue medication use were analysed. Another feature typical
of these studies is that the results favour the addition of
salmeterol more at early time points and this difference is
reduced as the study proceeds.
Salmeterol – other literature
Most of the studies mentioned above, (except ref [72]),
have recently been analysed in a meta-analysis [13]. In
addition, the published meta-analysis included 1 study (n
= 488) that remains unpublished at the present. At base-
line these patients (n = 3685, aged ≥12) used BDP 200 –
400 – 1000 µg/d or FP 200 – 500 µg/d. The addition of
salmeterol to those doses was compared with increasing
the dose of BDP or FP up to 2–2.5-fold. The mean FEV1
was <75% in most studies included in the meta-analysis
and a reversibility of ≥10–15% in PEF or FEV1 after inha-
lation of short-acting bronchodilator was required for
inclusion in all but three studies. In patients receiving sal-
meterol the morning PEF was 22–27 L/min greater and
FEV1 was 0.10 – 0.08 L greater after three to six months of
treatment, compared to the response to increased steroids.
Similarly, the mean percentage of days and nights without
symptoms was increased 12–15% and 5%, respectively, as
well as the mean percentage of days and nights without
need for rescue treatment increased 17–20% and 8–9%,
respectively.
Effect of LABA on asthmatic inflammation
The results of the above mentioned studies favour the
addition of a LABA instead of increasing the dose of ICS
in patients not adequately controlled with low to moder-
ate doses of ICS. However, there have been concerns that
regular use of inhaled β2-agonists may mask an increase in
the underlying airway inflammation in asthma. Also,
some proinflammatory effects have been described for β2-
agonists such as delay of constitutive eosinophil apopto-
sis [82] or reversal of corticosteroid-induced apoptosis
[83]. Furthermore, development of tolerance to their pro-
tective effects against various asthma-provoking stimuli
has been reported. There is some disagreement whether
the addition of formoterol or salmeterol changes the level
of pulmonary inflammation in patients already treated
with inhaled glucocorticoids or whether they may even
mask the inflammation. Three studies [84-86] do notPage 12 of 25
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ces following addition of formoterol or salmeterol,
whereas treatment of asthma with salmeterol with
concomitant steroid tapering has been shown to increase
the numbers of eosinophils in sputum [87].
Formoterol – studies included in this systematic review
In a randomised, double-blind and parallel-group study
(n = 61) with similar inclusion and exclusion criteria than
in the formoterol add-on study [67], the effect of adding
formoterol (12 µg bid) to a low dose of budesonide (200
µg/d) was compared with a higher dose of budesonide
(800 µg/d) for 1 year after a run-in with budesonide
(1600 µg/d) for 4-wk [84]. Budesonide (1600 µg/d) dur-
ing run-in significantly reduced median sputum eosi-
nophils. No significant changes in the proportion of
eosinophils, other inflammatory cells, or ECP levels in
sputum were observed over the ensuing one year treat-
ment with formoterol + budesonide (200 µg/d) or higher
dose budesonide (800 µg/d). Clinical asthma control was
not significantly different between both groups.
Salmeterol – other literature
In a small study (n = 9) with asthma patients using regular
inhaled glucocorticoids and inhaled salbutamol for symp-
tom relief, the addition of salmeterol for 8 weeks was
studied in a double-blind crossover placebo-controlled
protocol [86]. Bronchoalveolar lavage (BAL) cell profile,
albumin and tryptase levels, percentages of CD4+ and
CD8+ lymphocytes and lymphocyte activation as assessed
as proportions of lymphocytes expressing HLA-DR were
measured in BAL samples before and after treatment.
There were no significant changes after salmeterol treat-
ment. In another double-blind, parallel-group, placebo-
controlled study [85] the effect of addition of salmeterol
(50 µg bd) or fluticasone (200 µg/d) for 12 weeks was
studied in 45 symptomatic patients with asthma who
were receiving ICS (range 100–500 µg/d). Bronchial biop-
sies and BAL were analysed before and after the treatment.
After treatment with salmeterol there was no deterioration
of airway inflammation, as assessed by mast cell, lym-
phocyte, or macrophage numbers in BAL or biopsies, but
a significant fall in EG1-positive eosinophils in the lamina
propria was found, which was not seen after treatment
with FP. The only cellular effect of added FP was a
decrease in BAL lymphocyte activation as assessed as pro-
portions of lymphocytes expressing HLA-DR. There was a
concurrent improvement in clinical status, more marked
with salmeterol than with increased ICS. These two stud-
ies thus suggest that adding salmeterol to ICS is not asso-
ciated with increased airway inflammation. In another
study in 13 asthmatic individuals requiring ≥1500 µg ICS
daily, the steroid sparing and "masking" effects of salme-
terol versus placebo were studied in a randomised, pla-
cebo-controlled, double-blind and crossover trial [87].
Subjects were re-stabilised on their original dose of ICS for
4 wk before crossover to the alternative treatment. Corti-
costeroid doses were reduced weekly until criteria were
met for an exacerbation or the corticosteroid was fully
withdrawn. Mean ICS dose was reduced significantly
more (87%) during salmeterol treatment, than with pla-
cebo (69%). Sputum eosinophils increased before exacer-
bation, despite stable symptoms, FEV1 and PEF. In the
week before clinical exacerbation, sputum eosinophil
counts were higher in the salmeterol-treatment arm as
compared with placebo, whereas there were no differ-
ences in PC20 or serum ECP. Five subjects showed >10%
sputum eosinophilia before exacerbation during salme-
terol treatment, compared to two receiving placebo. This
suggests that the use of salmeterol allowed subjects to tol-
erate a greater degree of inflammation without increased
symptoms or reduced lung function. Thus, during pro-
gressive reduction of ICS the bronchodilator and symp-
tom-relieving effects of salmeterol may mask increasing
inflammation and delay awareness of worsening asthma.
These findings strengthen guideline recommendations
that LABA should not be described as sole anti-asthma
medication and that they should be used as "add-on"
therapy rather than for steroid tapering purposes.
The effect of addition of salmeterol (50 µg bd), FP (200
µg/d) or placebo for 3 months on airway wall vascular
remodelling has been studied in 45 symptomatic patients
with asthma who were receiving treatment with ICS
(range 400–1000 µg/d) [88]. Bronchial biopsies were ana-
lysed before and after treatment. There was a decrease in
the density of vessels of lamina propria after treatment
only in the salmeterol group compared to baseline. There
was no significant change within the FP or placebo groups
and no treatment was associated with increased airway
wall vascularity.
Asthma exacerbations
If there were a marked masking of pulmonary inflamma-
tion by LABA, one would expect to see an increase in the
number and severity of asthma exacerbations during their
long-term use. There is some difficulty in comparing the
different studies done with formoterol and salmeterol as
the definition of exacerbation varies. In formoterol studies
[67,68] a severe exacerbation was defined as need for treat-
ment with oral corticosteroids, as judged by the investiga-
tor, or hospital admission or emergency treatment for
worsening of asthma or a decrease in morning PEF >25%–
30% from baseline on two consecutive days. In contrast, in
the salmeterol "add-on" studies the exacerbation was not
defined at all or was more loosely defined for example as "a
clinical exacerbation", "any worsening of asthma symp-
toms requiring a change in prescribed therapy, other than
increased use of rescue medication" or "any asthma event
that required treatment with oral or parenteral steroids".Page 13 of 25
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In the formoterol study [67] the main outcome parameter
was the rate of exacerbations during combination therapy.
The results show that the 4-fold increase in the dose of
budesonide reduced the rates of severe and mild exacerba-
tions by 49% and 37%, respectively, whereas addition of
formoterol to the lower dose of budesonide reduced the
rates of severe and mild exacerbations by 26% and 40%,
respectively. Patients treated with formoterol and the
higher dose of budesonide had the greatest reductions,
63% and 62%, respectively (Figure 3B; Table 7, see Addi-
tional file 1). This suggests that if frequent asthma exacer-
bations are a major problem, increasing the dose of ICS
may help to reduce the number of exacerbations. The
results of the formoterol study [67] as well as the salme-
terol meta-analysis [13] suggest that addition of LABA has
divergent effects on asthma control: it is superior to the
increased steroid dose in improving lung function, but is
equal or less efficient in reducing exacerbations (Figure
3AB). The data also suggest that to achieve a better control
of asthma exacerbations, the dose of ICS should be
increased 4-fold. When 425 exacerbations of the formot-
erol study [67] were analysed [89], the use of higher dose
of ICS or the use of formoterol was shown not to affect the
pattern of change in PEF values or in symptoms during
asthma exacerbation (Figure 4B).
In contrast to that described in moderate to severe asthma,
in the other formoterol study [68] addition of formoterol
(6 µg bid) to either the lower (200 µg/d) or higher (400
µg/d) dose of budesonide in patients suffering from
mainly mild asthma reduced the risk of the first asthma
exacerbation by 43% (RR = 0.57, 95% CI 0.46–0.72).
There was also a significant 52% reduction in the rate of
severe exacerbations (RR = 0.48; 95% CI 0.39–0.59). In
addition, significant improvement was observed for the
rate of severe exacerbations (RR = 0.58, 95% CI 0.44–
0.76). Thus, the data suggest that there may be a difference
in the effect of ICS and formoterol on the exacerbations
between mild and moderate to severe asthma so that in
mild asthma addition of LABA may be more efficient in
preventing exacerbations, whereas in moderate to severe
asthma increasing the dose of ICS may be more efficient
(Table 7, see Additional file 1). However, the formoterol
studies [67,68] are not fully comparable in that way that
in the other study [67] the increase in the dose of budeso-
nide was 4-fold whereas in the other study [68] it was 2-
fold.
Another study [69] compared the addition of formoterol
(4.5 mg/d) to a small dose of budesonide (160 µg/d) in
single inhaler (Symbicort®) with an increased dose of
budesonide (400 µg/d) in adults with mild to moderate
asthma (mean FEV1 81–82%) not fully controlled on low
doses of ICS alone. Budesonide/formoterol combination
significantly decreased the relative risk of an asthma exac-
erbation by 26% as compared with higher dose budeso-
nide alone. In contrast, the estimated risk of having a
severe exacerbation was 6% lower in patients treated with
budesonide/formoterol compared with those receiving
budesonide alone, but this was not statistically
significant.
A. Change in supplemental salbutamol use before and after exacerbation in patients treated with fluticasone and salmeterol combination or with high-dose fluticason (with permission from ef 90), B. Change in morning PEF (percent fall fro  day -14) over the 14 d before a d 14 d af er n exac rbatio  in relation to treatment s analyz d f om a subgroup of a FACET study (with p rm ssion fro  ref 89)Figure 4
A. Change in supplemental salbutamol use before and after exacerbation in patients treated with fluticasone and salmeterol 
combination or with high-dose fluticasone (with permission from ref 90), B. Change in morning PEF (percent fall from day -14) 
over the 14 d before and 14 d after an exacerbation in relation to treatment as analyzed from a subgroup of a FACET study 
(with permission from ref 89).Page 14 of 25
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Only two studies [70,78] of those included in this system-
atic review reported the actual monthly or annual rates for
moderate or severe exacerbations. In those studies there
were no significant differences in the yearly rate of exacer-
bations or percentages of patients experiencing at least
exacerbation. The other studies generally reported the per-
centages of patients experiencing at least one exacerbation
(Table 7). In salmeterol studies, the data were presented
mostly in a form, which did not allow us to calculate the
yearly rate of exacerbations.
Salmeterol – other literature
In the salmeterol studies lasting 3–6 months the numbers
of patients with exacerbations were analysed. The meta-
analysis [13] revealed that fewer patients experienced any
exacerbation with salmeterol (difference 2.7%), and the
proportion of patients with moderate or severe exacerba-
tions was also lower (difference 2.4%). Thus, to prevent
one exacerbation 37–41 patients should be treated with
salmeterol instead of increasing the dose of ICS. Rather
than indicating salmeterol being superior, the result sug-
gests that there is no increased risk for exacerbations with
the use of salmeterol. Unfortunately, in most salmeterol
studies the severity and/or yearly incidence of exacerba-
tions was not analysed. As one patient can experience
more than one asthma exacerbation during the study, the
parameter used in the salmeterol studies (proportion of
patients experiencing an exacerbation) may not reflect the
actual number of exacerbations. Another factor that may
affect our interpretation of the effect of these therapies on
asthma exacerbations is that in 6 of the 12 LABA studies,
patients could be withdrawn from the study if they expe-
rienced >1–5 exacerbations (Table 7, see Additional file
1). This may underestimate the total incidence of exacer-
bations, as those patients experiencing several exacerba-
tions were excluded from analysis. However, these are the
patients the "add-on" therapies are most frequently
prescribed.
Recently, the exacerbation rates and clinical measures of
asthma worsening were assessed in an analysis combining
results from two double-blind studies (n = 925) compar-
ing addition of salmeterol to low-dose-FP with increasing
the dose of FP 2.5-fold [90]. The addition of salmeterol
resulted in a significantly lower rate (0.23 vs. 0.39 per
patient per year) of exacerbations compared with higher
dose FP. Salmeterol combined with low-dose FP was sig-
nificantly more protective than 2.5-fold higher dose of FP
in preventing asthma exacerbations, as assessed by the
time to first exacerbation. In both groups clinical indica-
tors of worsening of asthma showed parallel changes
before asthma exacerbation, and greater improvements in
morning PEF, supplemental salbutamol use and asthma
symptom score were observed after exacerbation with sal-
meterol compared with higher dose FP (Figure 4A). Thus,
the ability to detect deteriorating asthma and the severity
of exacerbation is not negatively affected by salmeterol.
Adverse effects of LABA
The addition of LABA to the treatment regimen usually
results in a slight increase in those pharmacologically pre-
dictable adverse events such as tremor and tachycardia.
However, generally these do not lead to the discontinua-
tion of the treatment. In the formoterol studies [67-69],
no significant differences were reported on the adverse
effects between the groups, but no detailed data was pre-
sented. Also, in the salmeterol studies [70-78], the inci-
dence of adverse events was very low and generally was
not different between the treatment groups. Although
LABA appear to be generally very safe, one should not for-
get that they are generally not suitable for patients with
symptomatic coronary heart disease or hyperthyroidism
and may provoke more severe adverse events such as
supraventricular tachycardias, atrial fibrillation and extra-
systoles. Rarely hypersensitivity reactions and painful
muscular cramps may occur. Also one should note that
the "add-on" studies included in this review are not origi-
nally planned and powered to detect significant differ-
ences in the adverse effects.
Adding a leukotriene receptor antagonist 
(LTRA)
Rationale
Cysteinyl leukotriene receptor-antagonists (LTRA), such
as montelukast, pranlukast and zafirlukast, are a new class
of asthma medication, whose role in the stepwise man-
agement of asthma has not yet been fully established. Leu-
kotriene antagonists blunt the obstructive response and
have weak anti-inflammatory activity. In some studies
corticosteroids are not very effective inhibitors of cysteinyl
leukotriene pathways, at least when assessed by their ina-
bility to reduce cysteinyl leukotriene concentrations
[91,92] and thus combination of these therapeutic classes
may offer some benefit.
Montelukast – studies included in this systematic review
We identified one randomised, double-blind, parallel-
group 16 week study (Jadad score 3) comparing the addi-
tion of montelukast (10 mg/d) to budesonide (800 µg/d)
with doubling the dose of budesonide (1600 µg/d) in
patients inadequately controlled on inhaled budesonide
(800 µg/d, n = 448) [93]. The inclusion criteria were:
patients (aged 15–75 years) who were not optimally con-
trolled as judged by the investigators in spite of a regular
ICS (600–1200 µg/d for BDP, budesonide, TAA, flu-
nisolide or 300–800 µg/d for FP). Patients were required
to have FEV1 ≥50% predicted at visits 1 and 3, with a≥12% bronchodilator response and symptoms requiring
β-agonist treatment of at least 1 puff/day during the last 2Page 15 of 25
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showed progressive improvement in several measures of
asthma control compared with baseline. Mean morning
PEF improved similarly in the last 10 weeks of treatment
compared with baseline in both the montelukast + budes-
onide group and in the double dose budesonide group
(33.5 vs 30.1 L/min). The improvement in montelukast +
budesonide group was faster as the mean morning PEF
was significantly higher during days 1–3 after start of
treatment in this group as compared with the double dose
budesonide group (20.1 vs 9.6 L/min) (Figure 5). Both
groups showed similar improvements with respect to
rescue β2-agonist use, mean daytime symptom score, noc-
turnal awakenings, exacerbations, asthma free days,
peripheral blood eosinophil counts, and asthma specific
quality of life. The authors conclude that addition of mon-
telukast to ICS offers comparable asthma control to dou-
bling the dose of ICS. However, it needs to be
remembered that, in most cases, to obtain a statistically
significant improvement in asthma control at least a 4-
fold increase in the dose of ICS is needed (see above).
Montelukast – other literature
A large (n = 639) study [94] recruited patients with
asthma not optimally controlled by ICS (stable dose
equivalent to budesonide 400–1600 µg/d). The patients
were required to have FEV1 ≥55%, a bronchodilator
response greater than 12%, symptoms and rescue β2 ago-
nist use of at least 1 puff/day. The mean FEV1 at baseline
was 81% predicted. The patients were randomised to
obtain either montelukast (10 mg/d) or placebo in a dou-
ble-blind manner. The ICS dose remained constant
throughout the study. The primary efficacy end point was
the percentage of asthma exacerbation days. The major
advantage of this study is that this study adopted several
different definitions for asthma exacerbation days from
previously published other studies, making comparison
to other studies more easy. The median percentage of
asthma exacerbation days was 35% lower (3.1% vs 4.8%,
p = 0.03) and the median percentage of asthma free days
was 56% higher (66.1% vs 42.3%, p = 0.001) in the mon-
telukast group than in the placebo group. Thus, the NNT
with montelukast to avoid one exacerbation day was 13,
and the NNT to avoid one day not free of asthma – that is,
to gain an asthma free day – was 10. Patients receiving
concomitant treatment with montelukast had signifi-
cantly less (25.6% vs 32.2%, p = 0.01) nocturnal awaken-
ings, and significantly greater reductions in β2-agonist use
(17.26% v 4.92%, p = 0.05, baseline use was 3.2–3.3
puffs/day), and morning PEF (16.86 L/min vs 11.30 L/
min, p = 0.05, baseline 365–373 L/min). No significant
difference was found in asthma specific quality of life or
in morning FEV1. The results of this study suggest that
although the effect of montelukast on endpoints such as
morning PEF, FEV1 and rescue β2-agonist use are only
small or modest, addition of montelukast may produce a
significant improvement of asthma control by reducing
the number of asthma exacerbation days.
In another study with patients (n = 642) with sympto-
matic persistent asthma despite the treatment with BDP
(400 µg/d), addition of montelukast (10 mg/d),
improved morning FEV1 and PEF, asthma symptom score
and the percentage of asthma exacerbation free days better
than placebo during 16 week treatment period [95]. The
increase in morning FEV1 was approximately 140 mL and
in morning PEF 10 L/min. There was a tendency towards
reduced rescue medication use with the combination
therapy, but the reduction was only 0.2 puffs/day. Addi-
tion of montelukast to ICS seemed to prevent the increase
in the number of peripheral blood eosinophils seen in
other treatment groups.
In an atypical "add-on" study (randomised double-blind,
placebo-controlled and crossover trial), addition of mon-
telukast (10 mg/d) was compared with placebo in patients
with asthma (n = 72) and symptoms despite treatment
with ICS and additional therapy [96]. Most of the patients
used several different types of combination therapy,
except leukotriene antagonists, at baseline. The inclusion
criteria were defined as "any patient with physician diag-
nosis of asthma in whom the recruiting physician felt a
trial of montelukast was indicated for continued asthma
symptoms despite other anti-asthma therapy". A current
Effect of addition of montelukast (10 mg/d) or doubling the dose of ICS on m rning p ak expiratory flow (AM PEF) over 12 week trea ment period in pa ien s not adequately con-trolled by budesonide 800 µg/d (solid line = mon lukas  +bud s nide 800 mg/d, dashed line = bud sonide 1600 µg/d) (with permissi  fro  ref 93)Figur 5
Effect of addition of montelukast (10 mg/d) or doubling the 
dose of ICS on morning peak expiratory flow (AM PEF) over 
12 week treatment period in patients not adequately con-
trolled by budesonide 800 µg/d (solid line = montelukast + 
budesonide 800 mg/d, dashed line = budesonide 1600 µg/d) 
(with permission from ref 93).Page 16 of 25
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ment, or worsening in the preceding month were both
exclusion criteria, but did not exclude any of those
referred for inclusion in the trial. In this setting corre-
sponding to a typical hospital outpatient clinic, addition
of montelukast did not result in any significant change in
symptom scores, rescue inhaled β2-agonist use, or morn-
ing or evening PEF. When treatment response was defined
as a 15% or greater increase in mean PEF recordings, there
were four responders to montelukast and seven respond-
ers to placebo. Although several points in this study may
be criticised (loose inclusion criteria, small sample size,
short 2 week treatment period, no wash-out period,
encapsulation of the tablets, exacerbations not analysed as
end-point), the results suggest that the effects of montelu-
kast are not as evident in unselected population than in
the more clearly defined patients included in other trials
[93-95].
The additional anti-inflammatory activity obtained by
adding montelukast to the treatment regimen has been
assessed in three randomised, double-blind, cross-over
studies lasting 10 days–8 weeks. In one study [97], addi-
tion of montelukast (10 mg/d) to salmeterol (50 µg bid)
and fluticasone (250 µg bid) combination was compared
with placebo in patients with mild-moderate asthma for 3
weeks. Compared with salmeterol/fluticasone run-in
period, adding montelukast was better (p < 0.05) than
placebo for inflammatory markers such as AMP-thresh-
old, recovery, exhaled NO, and blood eosinophils but not
for lung function. In another study [98], addition of mon-
telukast for 8 weeks to FP (100 µg bid) was compared with
placebo in patients with mild asthma. There were no dif-
ferences in FEV1 or histamine PC20 between the two treat-
ment regimens. There was no difference in the efficacy of
either treatment in decreasing T cell, CD45RO+, mast cell
or activated eosinophil numbers in bronchial biopsies. In
a third study [99], the addition of montelukast (10 mg/d)
to budesonide (400 µg/d) for 10 days to steroid-naïve
patients with asthma was reported not to produce any
additional anti-inflammatory benefit when compared
with budesonide alone in reducing airway hyperrespon-
siveness or sputum eosinophilia.
Zafirlukast – other studies
Addition of high-dose zafirlukast (80 mg b.i.d.: 4-fold
greater than the approved dose) improved asthma control
better than placebo in patients (n = 368) on high-dose ICS
(1000 – 4000 µg/d) [100]. Compared with placebo, addi-
tion of zafirlukast improved morning and evening PEF
and reduced daytime symptom score and rescue medica-
tion use [100]. According to a recent meta-analysis
[101,102], in symptomatic asthmatic adults, addition of
zafirlukast (80 mg bid) to ICS did not reduce the risk of an
exacerbation requiring systemic steroids after 12 weeks of
treatment, compared to double dose ICS [RR = 1.08; 95%
CI 0.47, 2.50]. There were no differences in any other
measure of outcome. Higher doses of zafirlukast than cur-
rently licensed were associated with increased risk of liver
enzyme elevation.
Conclusions on adding a LTRA
According to recent meta-analyses (12 adult studies and 1
in children) [101,102], leukotriene antagonists (zafirlu-
kast or pranlukast at 2–4 times the licensed dose) com-
bined with ICS (300–2000 µg/d BDP equivalent) reduce
the number of patients with exacerbations that require
systemic corticosteroids, compared to ICS alone [RR =
0.34; 95% CI 0.13, 0.88]. This equates to 20 patients
(95% CI 1,100) treated to prevent one needing systemic
corticosteroids. There was no difference in side effects
[101,102]. The addition of licensed doses of LTRA to ICS
resulted in a non-significant reduction in the risk of exac-
erbations requiring systemic steroids (two trials, RR 0.61,
95% CI 0.36, 1.05). This systematic review did not include
the recent study comparing the addition of montelukast
to double-dose ICS [93]. As that systematic review did not
include any data of LTRA drugs at currently licensed doses
compared with high dose ICS, the author came to a con-
clusion that the addition of LTRA to ICS may modestly
improve asthma control compared with ICS alone but this
strategy cannot be recommended as a substitute for
increasing the dose of ICS [101]. However, based on one
relatively large trial [93], the evidence suggests that addi-
tion of montelukast may be equal to doubling the dose of
ICS. However, one might criticise this conclusion as this
study [93] lacked placebo arm, ie. it is possible that
increasing (doubling) the dose of ICS does not produce
any real improvement in asthma control as compared
with lower ICS dose and thus the result showing non-infe-
riority to double dose ICS might mean no effect at all.
Thus, more data is needed to compare the efficacy of LTRA
at currently licensed doses with increasing the dose of ICS.
Adding theophylline
Rationale
Although theophylline has traditionally been classified as
a bronchodilator, its ability to control chronic asthma is
greater than can be explained by its relatively small degree
of bronchodilator activity. In fact, theophylline has
immunomodulatory, anti-inflammatory and broncho-
protective effects that may contribute to its efficacy as an
anti-asthma drug [103]. There is some evidence that addi-
tion of theophylline to ICS treatment improves pulmo-
nary function and asthma symptoms [104], although all
studies have not been able to confirm this result [105].
Theophylline – studies included in this systematic review
The addition of theophylline has been compared with
doubling the dose of ICS (BDP and budesonide; 400 µg/Page 17 of 25
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with symptomatic asthma for 6 to 12 weeks [106,107].
Theophylline was used at relatively low doses, the mean
serum theophylline concentrations were 8.7 and 10.1 mg/
L in these studies.
In the study (Jadad score 4) of Evans and coworkers [106]
addition of low-dose theophylline to budesonide (400
µg/d) was compared with doubling the dose of budeso-
nide (800 µg/d) in a randomised double-blind trial for 3
months. Patients (n = 62) were required to have FEV1 pre-
dicted normal ≥50%, bronchodilator response of at least
15% and to have symptoms despite the use of ICS (equiv-
alent to budesonide dose of 800–1000 µg/d). The overall
treatment effect of addition of theophylline was superior
to double-dose budesonide in improving FVC and FEV1
(Figure 6), although at single timepoints there were no
significant differences between the treatments. There was
no significant difference between the treatments in
improving home PEF recordings or reducing β2-agonist
use or symptom scores. There was no difference in the
occurrence of possibly drug-related adverse effects
between the groups. The statistical power of this study was
calculated to detect significant changes over baseline, but
not to detect differences (superiority) or non-inferiority
between the treatments.
A randomised, double-blind parallel-group study (Jadad
score 3) by Ukena and coworkers [107] compared the
addition of theophylline to low dose BDP (400 µg/d)
with double-dose BDP (800 µg/d) for 6 weeks. Patients (n
= 133) were required to have FEV1 50–85% predicted nor-
mal and a documented reversibility of at least 15% of
FEV1 over baseline and to be not controlled by BDP (400µg/d) or equivalent. The sample size of this study was
powered to detect equivalence. No significant differences
were found between the high-dose BDP and low-dose
BDP plus theophylline groups in outcomes such as morn-
ing or evening PEF, PEF variability, FEV1, daytime or
nighttime symptom scores or rescue medication use. Both
treatments were well tolerated.
Lim et al. [108] recruited asthmatic patients that were
symptomatic while being treated with low dose inhaled
steroids (400 µg BDP, 200 µg FP or 400 µg BDP daily).
Patients (n = 155) were required to have PEF ≥50% of the
predicted normal with at least 15% variability in PEF. The
patients were randomised to treatment either with low
dose BDP (400 µg/d) alone, theophylline plus BDP (400
µg/d) or high-dose BDP (1000 µg/d) for six months in a
double-blind trial (Jadad score 5). No significant
differences were found between any of the treatment
groups in morning PEF, evening PEF, PEF variability, res-
cue β2-agonist use, symptom scores or in the number of
exacerbations. Of note is that there were no difference
between the low dose BDP alone and high dose BDP
groups in any of the parameters. This study was powered
to detect superiority of theophylline plus BDP as com-
pared with high-dose BDP. There were no significant dif-
ferences between the treatment groups for any of the
commonly reported adverse effects. The results of this
study suggest that when the benefit of an "add-on" ther-
apy is evaluated as compared with double-dose inhaled
steroid, additional group using low-dose steroid alone
should be included to see whether even the doubling of
the dose of steroid produces any benefit to the patient.
Conclusions on the addition of theophylline
Taken together, the results from two relatively small stud-
ies suggest that addition of low-dose theophylline may be
equal to doubling the dose of ICS in the treatment of
asthma not adequately controlled by low dose of ICS.
However, one needs to remember that the effect of dou-
bling the dose of ICS on asthma control is generally small
or negligible (see above). Furthermore, a placebo group
should be included in these studies to see whether an
improvement in asthma control is obtained by doubling
the dose of ICS. Thus, more data is needed to confirm the
present results. Use of theophylline at concentrations at
the lower limit or slightly below the recommended thera-
peutic range may help to limit the adverse effects.
Comparison between LTRA, theophylline and 
LABA as add-on options
Montelukast versus salmeterol – studies included in this 
systematic review
Combination of fluticasone (100 µg bid) and salmeterol
(50 µg bid) in a single inhaler has recently been shown to
provide more effective asthma control than montelukast
(10 mg daily) combined with FP (100 µg bid) in a 12
weeks study (randomised, double-blind, double-dummy,
Jadad score 3) in patients (n = 447) whose symptoms
were suboptimally controlled by ICS only [109]. The
inclusion criteria were FEV1 between 50% and 80% pre-
dicted normal, and at least 1 additional sign of inadequate
asthma control during the 7 preceding days. Salmeterol/
FP combination was superior to montelukast/FP in
improving morning PEF (24.9 vs 13.0 L/min), evening
PEF (18.9 vs 9.6 L/min), FEV1 (0.34 vs 0.20 L) and short-
ness of breath symptom score (-0.56 vs -0.40) as well as
increasing the percentage of days without rescue medica-
tion (26.3 vs 19.1%). In contrast, there was no significant
difference in outcomes such as chest tightness, wheeze
and overall symptom scores. Asthma exacerbation rates
were significantly (P = 0.031) lower in the FP + salmeterol
group (2%) than in the FP+ montelukast group (6%).
Adverse event profiles were reported to be similar.
A similar study [110] comparing the efficacy of combina-
tion of FP (100 µg bid) and salmeterol (50 µg bid) in aPage 18 of 25
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daily) and FP (100 µg bid) in a 12 weeks study (ran-
domised, double-blind, double-dummy, Jadad score 4) in
patients (n = 725) whose symptoms were suboptimally
controlled by ICS (BDP, budesonide, flunisolide 400–
1000 µg/d or FP 200–500 µg/day) only. The inclusion cri-
teria were FEV1 above 50% and at least 15% bronchodila-
tor response, and asthma symptoms at least at 4/7 days
during run-in. Salmeterol/FP combination was superior
to montelukast/FP in improving morning PEF (36 vs 19 L/
min), evening PEF (29 vs 14 L/min), FEV1 (0.26 vs 0.17 L),
percentage of symptom-free days (42.9 vs 31.5%), per-
centage of symptom-free nights (46.5 vs 41.1%) as well as
increasing the percentage of days without rescue medica-
tion (47.9 vs 46%). In contrast, there was no significant
difference in percentage of rescue free nights. The number
of patients experiencing at least one asthma exacerbation
(any severity) was significantly (P < 0.05) lower in the FP
+ salmeterol group (9.6%) than in the FP+ montelukast
group (14.6%). The percentage of patients who had at
least one asthma exacerbation of either moderate or
severe intensity was 4.8% in the salmeterol + FP group
and 8.4% in the montelukast + FP group, but this differ-
ence did not reach statistical significance. The time to the
first exacerbation was significantly (P < 0.05) longer in the
salmeterol + FP group than in the montelukast + FP group.
Adverse event profiles were reported to be similar.
Another very similar study [111] was designed to demon-
strate the non-inferiority of combination of montelukast
(10 mg daily) and FP (100 µg bid in dry powder inhaler)
as compared with combination of FP (100 µg bid in dry
powder inhaler) and salmeterol (50 µg bid; metered dose
inhaler) on asthma exacerbations. This 48 weeks study
(randomised, double-blind, double-dummy, Jadad score
5) included patients (n = 1490) whose symptoms were
suboptimally controlled by ICS (equivalent to BDP 200–
1000 µg/d). The inclusion criteria were FEV1 50–90% pre-
dicted and at least 12% bronchodilator response, short-
acting β2-agonist use of one puff/day or more and asthma
symptoms. Salmeterol/FP combination was superior to
montelukast/FP in improving morning PEF (34.6 vs 17.7
L/min), FEV1 (0.19 vs 0.11 L). In contrast, there was no
significant difference in nocturnal awakenings and
asthma specific quality of life score. The percentage of
patients experiencing at least one asthma exacerbation
(any severity) was shown to be similar in the FP +
salmeterol group (19.1%) than in the FP+ montelukast
group (20.1%). Also there was no difference in the time to
the first exacerbation between the salmeterol + FP and the
montelukast + FP groups. Peripheral blood eosinophils
Mean (+- SE) change in FEV1 in 31 asthma patients treated with high-dose budesonide (1600 µg/d) and 31 patients given low-dose budesonide (800 µg/d) a d theophylline (with p rmission from ref 106)Figure 6
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montelukast + FP group (-0.04 × 103/µl) than in the salm-
eterol + FP group (-0.01 × 103/µl). Interestingly more seri-
ous adverse events were reported in the salmeterol + FP
group.
In another randomised, double-blind, double-dummy,
parallel-group study (Jadad score 3) in patients (n = 948)
with symptomatic asthma despite treatment with ICS,
addition of montelukast (10 mg daily) was compared
with addition of salmeterol (50 µg bid) for 12 weeks
[112]. Patients were required to have symptoms despite
the constant dose of ICS (any brand at any dose) and FEV1
between 50% and 80% predicted and at least 12% bron-
chodilator response. Treatment with salmeterol resulted
in significantly greater improvements from baseline com-
pared with montelukast for most efficacy measurements,
including morning PEF (35.0 vs 21.7 L/min), percentage
of symptom-free days (24 v 16%) and percentage of res-
cue-free days (27 vs 20%). Also total supplemental salb-
utamol use (-1.90 vs -1.66 puffs per day) and nighttime
awakenings per week (-1.42 vs -1.32) decreased signifi-
cantly more with salmeterol than with montelukast. Six
percent of patients in the salmeterol group experienced a
total of 27 asthma exacerbations compared with 5% of
patients in the montelukast group who experienced 24
asthma exacerbations during the 12 weeks treatment
period. However, the patients experiencing an asthma
exacerbation were withdrawn from the study. Thus, annu-
alised incidences of exacerbations cannot be compared
[112]. The safety profiles of the two treatments were
reported to be similar.
Taken together, addition of salmeterol seems to produce
better improvement of asthma control when lung func-
tion is assessed than addition of montelukast in patients
with asthma suboptimally controlled by small to moder-
ate doses of ICS. However, in one long-term study [111]
addition of montelukast to fluticasone was shown to be
non-inferior to addition of salmeterol when the percent-
age of patients with at least one asthma exacerbation was
used as the primary endpoint. Whereas addition of salm-
eterol may produce a better improvement in lung func-
tion, addition of montelukast may provide additional
anti-inflammatory efficacy to ICS that is reflected in a
long-term efficacy on asthma exacerbations. A factor that
may produce a selection bias in these studies [109-111] is
that a positive response to bronchodilator was required
for inclusion. In fact, the reported mean improvements in
FEV1 in response to β2-agonist were 23–24% [109], 27.0–
27.4% [110] and 18.4–18.8% [111] in the single studies.
This may produce a selection bias favouring long-acting
β2-agonist. However, one needs to remember that many
of those studies done with leukotriene receptor antagonist
to prove their efficacy in the treatment of asthma have
been performed with patients displaying a significant
response to β2-agonist. Another factor that might be con-
sidered to produce bias is that all the above three studies
that report salmeterol to be better have been sponsored by
the producer of salmeterol and that study reporting the
non-inferiority of montelukast as compared with salme-
terol has been sponsored by producer of montelukast.
Montelukast versus salmeterol – other literature
In addition to the normal clinical endpoints, the effects of
addition of salmeterol (50 µg bid) or montelukast (10
mg/d) to the treatment regimen were analysed on AMP
bronchial challenge, blood eosinophil counts and
exhaled NO in a placebo-controlled, double-dummy,
crossover study in patients (n = 20) with persistent asthma
not controlled with ICS [113]. For the provocative con-
centration of AMP causing a 20% fall in FEV1, compared
to placebo, there were significant differences with the first
and last doses of montelukast as well as the first but not
the last dose of salmeterol, thus indicating the develop-
ment of some tolerance with salmeterol. Only
montelukast produced a significant, albeit trivial, suppres-
sion of blood eosinophil count. There were significant
improvements with the first doses of salmeterol for all
parameters of lung function. After 2 weeks of treatment,
there were significant improvements with both drugs on
rescue bronchodilator requirement and morning PEF.
There were no significant differences between drugs for
any endpoints except blood eosinophils. Thus, the results
suggest some anti-inflammatory activity for montelukast
when used as an "add-on" therapy.
Salmeterol versus zafirlukast – studies included in this 
systematic review
In a randomised, double-blind, double-dummy parallel-
group trial (Jadad score 3) addition of zafirlukast (20 mg
bid) was compared with the addition of salmeterol (50 µg
bid via MDI) for 4 weeks in adult and adolescent patients
(n = 429) with persistent asthma [114]. Patients were
required to have FEV1 percentage predicted normal
between 50 and 70% with or without asthma symptoms,
or FEV1 of 70.1% to 80% of predicted normal values and
symptoms or requirement for rescue β2-agonist use ≥4
puffs/day or diurnal PEF-variation of more than 20% at
two days during 6 days run-in. Both inhaled salmeterol
and oral zafirlukast resulted in within-group improve-
ments from baseline in measures of pulmonary function
(morning and evening PEF and FEV1), asthma symptoms,
and supplemental salbutamol use. Salmeterol treatment
resulted in significantly greater improvements from base-
line compared with zafirlukast for most efficacy
measurements, including morning PEF (28.8 vs 13.0 L/
min), evening PEF (21.8 vs 11.2 L/min), combined
patient-rated symptom scores for all symptoms (-35 vs
21%), daytime albuterol use (41 vs 25%) and night-timePage 20 of 25
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cant differences favouring the addition of salmeterol were
noted on patient-rated symptom scores for shortness of
breath and chest tightness, percentage of symptom-free
days, sleep symptoms, nighttime awakenings and percent-
age of days and nights with no albuterol use. There was no
difference between the groups in symptom score for
wheezing. Interestingly, the difference between salmeterol
and zafirlukast was clear at week 1, but not at 4 weeks
when the effect on FEV1 was analysed. One factor that may
affect the results of this study is that there may be a ran-
domisation bias as the proportions of patients using FP or
TAA were not similar in the salmeterol and zafirlukast
groups. This study was funded by the producer of
salmeterol.
Salmeterol versus zafirlukast – other literature
As a part of the above study [114], a randomised, double-
blind, double-dummy parallel-group trial comparing the
addition of zafirlukast (20 mg b.i.d) with the addition of
salmeterol (50 µg bid) for 4 weeks in patients (n = 289)
with persistent asthma, 80% of whom were on a concur-
rent ICS regimen has been published [115]. Both inhaled
salmeterol and oral zafirlukast resulted in within-group
improvements from baseline in measures of pulmonary
function (morning and evening PEF and FEV1), asthma
symptoms, and supplemental salbutamol use. Salmeterol
treatment resulted in significantly greater improvements
from baseline compared with zafirlukast for most efficacy
measurements, including morning PEF (29.6 vs 13.0 L/
min), percentage of symptom-free days (22.2% vs 8.8%)
and percentage of days and nights with no supplemental
albuterol use (30.5% vs. 11.3%).
Formoterol versus zafirlukast versus theophylline – other 
literature
An open, randomised Turkish study [116] recruited
patients with moderate persistent asthma having symp-
toms despite the use of moderate to high doses of ICS. The
patients were required to have a FEV1 reversibility of at
least 15%. Patients (n = 64) were randomised to three dif-
ferent treatments budesonide (800 µg/d) plus formoterol
(9 µg bid), budesonide (800 µg/d) plus zafirlukast (20 mg
bid) or budesonide (800 µg/d) plus sustained-release the-
ophylline (400 mg/d) for three months. After three
months there were no between group differences in end-
points such as morning and evening PEF, PEF variability,
FEV1, daytime or nighttime symptom scores and rescue
terbutaline use. However, the addition of formoterol pro-
duced earlier improvements compared with the two other
groups in criteria such as PEF variability, day- and night-
time asthma symptom scores and supplemental terbuta-
line use. Patients in budesonide plus zafirlukast group
experienced most adverse effects, but no statistical
analysis was presented. The authors conclude that in
patients who still have symptoms despite the treatment
with ICS, the addition of any of these medications to the
treatment is a logical approach and may be chosen.
Conclusions on the comparisons between LABA, LTRA and 
theophylline as add-on options
LABA (salmeterol) seem to have superior efficacy as add-
on therapy in persistent asthma not controlled by low to
moderate doses of ICS as compared with LTRA (montelu-
kast; four studies or zafirlukast; one study). More studies
comparing the different add-on options are needed as
well as studies with longer duration as the current evi-
dence is mostly limited to follow-up period of 3 months.
Compliance and treatment strategies
When assessing a patient with persistent asthma who is
not adequately controlled by low to moderate doses of
ICS:
• It is important to find out whether the patient is using
the prescribed medication correctly. Poor compliance in
asthma patients treated with ICS is a very common reason
for treatment failure. Compliance with ICS is often less
than 50% [117,118]. Oral asthma therapies may result in
better compliance [119].
• Secondly, it is important to check whether the inhala-
tion technique is adequate. Problems with the inhalation
techniques are very common, especially among children
and the elderly [120]. Good patient education, especially
if it is self-management oriented improves health out-
comes in adults with asthma [121].
• Thirdly, it is important to search for possible environ-
mental factors, such as changes in home and working
environment, hobbies and pets.
If asthma exacerbations are the dominant problem,
guided self-management of asthma has been proven to be
an efficient treatment strategy. In a Cochrane review [121]
self-management of asthma was compared with usual care
in 22 studies. Self-management reduced hospital admis-
sions (odds ratio; OR 0.58, 95% confidence interval; CI
0.38 to 0.88), emergency room visits (OR 0.71; 95% CI
0.57–0.90), unscheduled visits to the doctor (OR 0.57;
95% CI 0.40 to 0.82), days off from work or school (OR
0.55; 95% CI 0.38 to 0.79) and nocturnal asthma (OR
0.53; 95% CI 0.39 to 0.72).
Conclusions
Addition of formoterol or salmeterol seems to be superior
as compared with the increase in the dose of the ICS in
improving lung function, controlling asthma symptoms
and reducing the use of rescue bronchodilator treatment.
By increasing (doubling) the dose of the ICS the clinicalPage 21 of 25
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if frequent exacerbations are the major problem, increas-
ing the dose of ICS may significantly help to reduce the
number of exacerbations. By avoiding doses above 1000 –
1500 µg/d (budesonide and BDP) or 500 – 750 µg/d (FP)
the risk of systemic adverse effects remains low. However,
it should be noted that the evidence on the superiority of
LABA is limited to symptomatic patients with mild to
severe persistent asthma currently treated with low to
moderate doses of ICS and presenting with a significant
bronchodilator response. Also, addition of the LTRA
montelukast or zafirlukast may improve asthma control
in patients remaining symptomatic with ICS and addition
of montelukast may be equal to double-dose ICS. Addi-
tion of LABA (salmeterol) seems to produce better asthma
control as compared with a LTRA (montelukast or zafirlu-
kast) whereas the long-term efficacy of LTRA (montelu-
kast) on asthma exacerbations may be equal to LABA
(salmeterol). There is evidence that addition of low-dose
theophylline to the treatment regimen may be equal to
doubling of the dose of ICS. However, more studies are
needed to better clarify the role of leukotriene antagonists
and theophylline as "add on"-therapies. For patients with
inappropriate inhalation technique the value of LTRA or
theophylline are especially worth considering. More stud-
ies are now needed to compare between different add-on
therapies and to explore the effect of more than one add-
on therapy in patients with more severe asthma as well as
in those having symptoms but not significant bronchodi-
lator response.
Another issue not addressed by these studies of large
patient groups are the different responses of patients to
the different add-on therapies. This needs to be studied by
comparing add-on treatments in the same patients, but
these studies are difficult and prolonged. In the future it
may be possible to predict factors that predict the value of
a particular add-on therapy in a particular patient, but the
currently published studies unfortunately provide no
guidance.
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